The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]


Variant: NM_000156.6(GAMT):c.481A>T (p.Lys161Ter)

CA16608969

392462 (ClinVar)

Gene: GAMT
Condition: guanidinoacetate methyltransferase deficiency
Inheritance Mode: Autosomal recessive inheritance
UUID: 88568db0-9192-4742-8199-f7371c8a2255

HGVS expressions

NM_000156.6:c.481A>T
NM_000156.6(GAMT):c.481A>T (p.Lys161Ter)
NC_000019.10:g.1399005T>A
CM000681.2:g.1399005T>A
NC_000019.9:g.1399004T>A
CM000681.1:g.1399004T>A
NC_000019.8:g.1350004T>A
NG_009785.1:g.7549A>T
ENST00000252288.8:c.481A>T
ENST00000447102.8:c.481A>T
ENST00000591788.3:n.164A>T
ENST00000640164.1:n.314A>T
ENST00000640762.1:c.412A>T
ENST00000252288.6:c.481A>T
ENST00000447102.7:c.481A>T
ENST00000591788.2:n.166A>T
NM_000156.5:c.481A>T
NM_138924.2:c.481A>T
NM_138924.3:c.481A>T

Likely Pathogenic

The Expert Panel has overridden the computationally generated classification - "Uncertain Significance - Insufficient Evidence"
Met criteria codes 2
PM2_Supporting PVS1

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Cerebral Creatine Deficiency Syndromes Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for GAMT Version 1.1.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Cerebral Creatine Deficiency Syndromes VCEP
The NM_000156.6:c.481A>T (p.Lys161Ter) variant in GAMT is a nonsense variant predicted to cause a premature stop codon in biologically relevant exon 5/6. While the variant is in the penultimate exon of GAMT, it is upstream of the region predicted to be missed by nonsense-mediated decay, and this is expcetd to lead to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00002 (2/128668 alleles) in the European (non-Finnish) population, which is lower than the ClinGen CCDS VCEP’s threshold for PM2_Supporting (<0.0004), meeting this criterion (PM2_Supporting). There is a ClinVar entry for this variant (Variation ID: 392462). To our knowledge, this variant has not been reported in an individual with GAMT deficiency in the published literature. The classification of this variant has been upgraded from Variant of Uncertain Significance to Likely Pathogenic based on the recommendations of the ClinGen Sequence Variant Interpretation Working Group, that a variant meeting PVS1 and PM2_Supporting is classified as Likely Pathogenic (https://clinicalgenome.org/site/assets/files/5182/pm2_-_svi_recommendation_-_approved_sept2020.pdf ). In summary, this variant meets the criteria to be classified as likely pathogenic for GAMT deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 1.1.0): PVS1, PM2_Supporting. (Classification approved by the ClinGen CCDS VCEP on March 9, 2023)
Met criteria codes
PM2_Supporting
The highest population minor allele frequency in gnomAD v2.1.1 is 0.00002 (2/128668 alleles) in the European (non-Finnish) population, which is lower than the ClinGen CCDS VCEP’s threshold for PM2_Supporting (<0.0004), meeting this criterion (PM2_Supporting).
PVS1
The NM_000156.6:c.481A>T (p.Lys161Ter) variant in GAMT is a nonsense variant predicted to cause a premature stop codon in biologically-relevant-exon 5/6. While the variant is in the penultimate exon of GAMT, it is upstream of the region predicted to be missed by nonsense-mediated decay, and this is expcetd to lead to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1).
Approved on: 2023-03-09
Published on: 2023-03-09
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.